anti-CD19 CAR-T cell therapy (Shanghai Tongji Hospital)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-CD19 CAR-T cell therapy (Shanghai Tongji Hospital)
Drug Alias Nameanti-CD19 CAR-T cell therapy (Shanghai Tongji Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Tongji Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Tongji Hospital
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A